logo
Guardant Health presented results of largest study on ctDNA in colon cancer

Guardant Health presented results of largest study on ctDNA in colon cancer

Guardant Health (GH) presented results of the largest study to date evaluating circulating tumor DNA, ctDNA, in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology Annual Meeting. Results demonstrated that circulating tumor DNA detected in the bloodstream after cancer surgery and prior to the start of adjuvant therapy, using the Guardant Reveal test, is a strong predictor of the risk of disease recurrence and poorer survival, and suggest the potential for ctDNA testing to improve decision-making at a critical time point for post-operative chemotherapy. Specifically: Among patients with post-surgical ctDNA detected, 62.6% had the cancer return within 3 years, despite having had adjuvant chemotherapy, while only 15.4% of patients with undetectable ctDNA recurred in the same period. The level of ctDNA, or tumor fraction, showed promise in identifying individuals who are less likely to clear residual disease with adjuvant treatment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hand soaps voluntarily recalled due to bacteria that can cause life-threatening infections

time28 minutes ago

Hand soaps voluntarily recalled due to bacteria that can cause life-threatening infections

A New Jersey-based medical care and skin care products manufacturer is voluntarily recalling multiple types of hand soap, cleanser and antiseptic products due to bacteria contamination. DermaRite Industries, LLC announced a recall of its DermaKleen antiseptic lotion soap with vitamin E in 1,000-milliliter and 800-milliliter sizes, as well as KleenFoam antibacterial foam soap with aloe vera (1,000-milliliter sizes), DermaSarra external analgesic (7.5-ounce sizes), and PeriGiene antiseptic cleanser (7.5-ounce sizes), all of which were distributed in the U.S. and Puerto Rico. Impacted products have expiration dates ranging from July 2025 to February 2027. A full list of affected lot and reorder numbers can be found here. The company recall announcement, dated Aug. 8, was also shared on the U.S. Food and Drug Administration website over the weekend. DermaRite said in its announcement that the impacted products are contaminated with Burkholderia cepacia, a type of bacteria that can cause serious or life-threatening infections. "The contaminated products may be used by immunosuppressed individuals or by people attending to immunosuppressed individuals," DermaRite stated. "In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis." The Centers for Disease Control and Prevention states that Burkholderia cepacia, also referred to as B. cepacia or Bcc, often spreads through soil and water sources, in addition to contaminated surfaces and products and through person-to-person contact. When someone is infected with the bacteria, they may not exhibit any symptoms. If they do show symptoms, they may experience respiratory issues or a fever or fatigue. High Noon voluntarily recalls some vodka seltzer drinks that were mislabeled as Celsius energy drinks People who are immunocompromised or those with chronic lung conditions including cystic fibrosis are at higher risk of becoming infected with B. cepacia, according to the CDC. The bacteria can also be resistant to antibiotics, making infections difficult to treat, the CDC states. DermaRite said it has already notified its distributors and customers via e-mail "to immediately examine available inventory" and to destroy any recalled products "in accordance with each facility's process." The company said it has not received any reports of adverse reactions in connection with the recall. Anyone experiencing symptoms after product use should consult with their health care provider and report adverse reactions to the FDA's MedWatch Adverse Event Reporting program, it added. Customers with questions or those in need of further information on the recall can contact DermaRite by phone at (973) 569-9000, extension 104, Monday through Friday from 9 a.m. to 5 p.m. EST, or via email at

Hand soaps, cleansers voluntarily recalled due to bacteria contamination

timean hour ago

Hand soaps, cleansers voluntarily recalled due to bacteria contamination

A New Jersey-based medical care and skin care products manufacturer is voluntarily recalling multiple types of hand soap, cleanser and antiseptic products due to bacteria contamination. DermaRite Industries, LLC announced a recall of its DermaKleen antiseptic lotion soap with vitamin E in 1,000-milliliter and 800-milliliter sizes, as well as KleenFoam antibacterial foam soap with aloe vera (1,000-milliliter sizes), DermaSarra external analgesic (7.5-ounce sizes), and PeriGiene antiseptic cleanser (7.5-ounce sizes), all of which were distributed in the U.S. and Puerto Rico. Impacted products have expiration dates ranging from July 2025 to February 2027. A full list of affected lot and reorder numbers can be found here. The company recall announcement, dated Aug. 8, was also shared on the U.S. Food and Drug Administration website over the weekend. DermaRite said in its announcement that the impacted products are contaminated with Burkholderia cepacia, a type of bacteria that can cause serious or life-threatening infections. "The contaminated products may be used by immunosuppressed individuals or by people attending to immunosuppressed individuals," DermaRite stated. "In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis." The Centers for Disease Control and Prevention states that Burkholderia cepacia, also referred to as B. cepacia or Bcc, often spreads through soil and water sources, in addition to contaminated surfaces and products and through person-to-person contact. When someone is infected with the bacteria, they may not exhibit any symptoms. If they do show symptoms, they may experience respiratory issues or a fever or fatigue. People who are immunocompromised or those with chronic lung conditions including cystic fibrosis are at higher risk of becoming infected with B. cepacia, according to the CDC. The bacteria can also be resistant to antibiotics, making infections difficult to treat, the CDC states. DermaRite said it has already notified its distributors and customers via e-mail "to immediately examine available inventory" and to destroy any recalled products "in accordance with each facility's process." The company said it has not received any reports of adverse reactions in connection with the recall. Anyone experiencing symptoms after product use should consult with their health care provider and report adverse reactions to the FDA's MedWatch Adverse Event Reporting program, it added. Customers with questions or those in need of further information on the recall can contact DermaRite by phone at (973) 569-9000, extension 104, Monday through Friday from 9 a.m. to 5 p.m. EST, or via email at

Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly
Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly

Geek Wire

time2 hours ago

  • Geek Wire

Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly

Jiafei Duan, Ai2 researcher, shows MolmoAct controlling a robotic arm. (GeekWire Photo / Todd Bishop) The Allen Institute for AI released a new AI robotics system that uses novel approaches to help robots navigate messy real-world environments, while making all of the model's code, data, and training methods publicly available under open-source principles. The system, called MolmoAct, converts 2D images into 3D visualizations, previews its movements before acting, and lets human operators adjust those actions in real time. It differs from existing robotics models that often work as opaque black boxes, trained on proprietary datasets. Ai2 expects the system to be used by robotics researchers, companies, and developers as a foundation for building robots that can operate in unstructured environments such as homes, warehouses, and disaster response scenes. In demos last week at Ai2's new headquarters north of Seattle's Lake Union, researchers showed MolmoAct interpreting natural language commands to direct a robotic arm to pick up household objects, such as cups and plush toys, and move them to specific locations. Researchers described it as part of AI2's broader efforts to create a comprehensive set of open-source AI tools and technologies. The Seattle-based research institute was founded in 2014 by the late Microsoft co-founder Paul Allen, and is funded in part by his estate. Ai2's flagship OLMo large language model is a fully transparent alternative to proprietary systems, with openly available training data, code, and model weights, designed to support research and public accountability in AI development. The institute's projects are moving in 'one big direction' — toward a unified AI model 'that can do reasoning and language, that can understand images, videos, that can control a robot, and that can make sense of space and actions,' said Ranjay Krishna, Ai2's research lead for computer vision, and a University of Washington Allen School assistant professor. MolmoAct builds on AI2's Molmo multimodal AI model — which can understand and describe images — by adding the ability to reason in 3D and direct robot actions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store